| |
Adam I. Riker, M.D., F.A.C.S. |
|
|
| |
| Translational Research Scientist, Associate Professor of Surgery and Chief of Surgical Oncology, Abraham A. Mitchell Clinical Research Scholar, Mitchell Cancer Institute, University of South Alabama |
| |
| Contact Information: |
Medical Sciences Building, Room 2015,
Mitchell Cancer Institute-University of South Alabama
307 North University Blvd., Mobile, Alabama 36688
Office: 251-460-6993
Fax: 251-460-6994
email: ariker@usouthal.edu |
| |
|
| Background: |
B.S., University of South Florida, College of Natural Sciences, Biology, Cum Laude, 1987
M.D., University of South Florida, College of Medicine, Medical Doctor, 1994
Residency in General Surgery, Loyola University Affiliated Hospitals and Medical Center, 1994-96, 1999-2002
Clinical and Research Fellowship in Surgical Oncology and Immunotherapy of Cancer, National Institutes of Health / National Cancer Institute / Surgery Branch, 1996-1999
Assistant Professor of Surgery, Department of General Surgery, Division of Surgical Oncology, Cardinal Bernardin Cancer Center, Loyola University Medical Center, 2002-2003
Assistant Professor of Surgery, Department of Interdisciplinary Oncology, Cutaneous Oncology & Comprehensive Breast Cancer Program, Experimental Therapeutics & Immunology Program, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Department of Surgery, 2003-2006
Associate Professor of Surgery and Chief of Surgical Oncology, Abraham A. Mitchell Clinical Research Scholar
|
| |
| Board of Certification and Fellowship: |
Fellowship, Surgical Oncology
Fellow, American College of Surgeons, Active
General Surgery, Diplomate, American Board of Surgery, Certificate # 048093, Active, Issue Date 04/03/2003 |
| |
| Research Interests: |
Our laboratory is primarily interested in the metastasis of cancer, currently focusing on the (epi)genetic mechanisms involved in the malignant transformation, progression and metastasis of melanoma. Most of our research is translational in nature, bringing new concepts and discoveries into the clinic in the form of novel, early phase experimental clinical trials for patients with advanced cancer.
Development of experimental immunotherapeutic cancer “vaccines” for the implementation of investigator-initiated, early phase clinical trials for patients with metastatic melanoma
|
| |
| Selected Recent Publications : |
| Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, Sullivan DM, Munster PN, Ugen KE, Messina JL, Heller R. First human trial of in vivo electroporation mediated gene transfer: safety profile and tumor regression after IL-12 plasmid delivery to metastatic melanoma patients. Submitted to Journal of Clinical Oncology, 2008 |
| |
| Riker AI, Enkemann SA, Fodstad O, Liu S, Ren S, Briggs J, Morris C, Xi Y, Howell P, Metge B, Samant RS, Shevde LA, Li WB, Sondak VK, Daud AI, Messina J, Ju JJ, Matta J. Genetic and Molecular Interrogation of Human Melanoma Yields a Metastatic Signature and Transition Point of Progression and Metastasis. Submitted to Biomed Central Medical Genomics (BMC Medical Genomics), 2008 |
| |
| Hagmaier RM, D’Alessio MJ, Nelson GA, Daniels LJ, Riker AI. Successful Removal of a Giant Intrathoracic Lipoma: A Case Report and Review of the Literature. Submitted to Hematology and Oncology, 2008 |
| |
| Daud AI, Mirza D, Andrews S, Urbas P, Gao GX, Lee JH, Sondak VK, Riker AI, DeConti RC, Gabrilovich D. A phase II study of high-risk melanoma patients treated with adjuvant GM-CSF. Submitted to Journal of Clinical Oncology, 2008 |
| |
| Dennis TR, Cunliffe HE, Wattendorf DJ, Sood R, Pollock PM, Zhang J, Walker R, Glatfelter AA, Lueders J, Faruque M, Raptoulis GN, Loda R, Wallace MR, Sondak VK, White WL, Halaban R, Riker AI, Meltzer PS, Trent JM. TTK (hMps1) kinase mitotic checkpoint gene: Relationship to chromosome 6q14.3 rearrangements and centrosome amplification in melanoma. Submitted to Cancer Genetics and Cytogenetics, 2008 |
| |
| Ren S, Liu S, Howell P, Xi Y, Ju JJ, Riker AI. The Impact of Genomics in Understanding Human Melanoma Progression and Metastasis. In press, Cancer Control, 2008 |
| |
|
Matsushita N, Pilon-Thomas SA, Kuhn LM, Riker AI. Comparative methodologies of regulatory T-cell depletion in a murine melanoma model. In press, Journal of Immunological Methods, 2008
|
| |
| Ju JJ, Liu S, Ren S, Xi Y, Howell P, Riker AI. Oncogenomics- Dissecting Cancer Through Genome Research. In Press, Expert Opinion in Biological Therapy (EOBT), 2008 |
| |
| Xi X, Riker AI, Samant L, Morris C, Gavin E, Fodstad O, Ju JJ. Global comparative gene expression analysis of melanoma patient samples, derived cell lines and corresponding tumor xenografts. In Press, Cancer Genomics and Proteomics, 2008
|
| |
|
Cox CE, Kiluk JV, Riker AI, Cox JM, Allred N, Ramos DC, Dupont EL, Vrcel V, Diaz N, Boulware D. The significance of sentinel lymph node micrometastases in human breast cancer. Journal of the American College of Surgeons (JACS), 206(2), 261-268, 2008
|
| |
| Riker AI, D’Alessio MJ, Hagmaier RM, Glass LF, Cruse CW. The surgical management of cutaneous melanoma. Giornale Italiano Di Dermatologia E Venerologia. 142, 171-195, 2007 |
| |
| Jensen EH, Lewis JM, McLoughlin JM, Alvarado MD, Daud A, Messina J, Enkemann S, Yeatman TJ, Sondak VK, Riker AI. Down-regulation of pro-apoptotic genes is an early event in the progression of malignant melanoma. Annals of Surgical Oncology, 14(4), 1416-1423, 2007 |
| |
|
Riker AI, Radfar S, Wang YX, Liu SH, Khong H. Immunotherapy of Melanoma. Expert Opinion in Biologic Therapy, 7(3), 345-358, 2007
|
| |
| Mohapatra S, Coppola D, Riker AI, Pledger JW. Roscovitine inhibits differentiation and invasion in a 3-dimensional skin reconstruction model of metastatic melanoma. Molecular Cancer Research, 5(2), 145-151, 2007 |
| |
|
Xi Y, Nakajima G, Hamil T, Fodstad O, Riker AI, Ju J. Association of insulin-like growth factor binding protein (IGFBP-3) expression with melanoma progression. Molecular Cancer Therapeutics, 5(12), 3078-3084, 2006
|
| |
| Riker AI, Kirksey L, Thompson L, Morris A, Cruse CW. Current Surgical Management of Melanoma. Expert Review of Anti-Cancer Therapy, 6(11), 1569-1583, 2006 |
| |
| Pilon-Thomas S, Li WB, Briggs J, Djeu J, Mule JJ, Riker AI: Immunostimulatory effects of CpG-ODN upon dendritic cell-based immunotherapy in a murine melanoma model. Journal of Immunotherapy, July/August 29(4), 381-87, 2006 |
| |
| Riker AI, Daud A, Jove R: Recent Advances in Melanoma, Frontiers in Bioscience, January 1st, 11, 1-14, 2006 |
| |
| Pilon-Thomas S, Verhaegen M, Kuhn L, Riker AI, Mulé JJ: Induction of anti-tumor immunity by vaccination with dendritic cells pulsed with anti-CD44 IgG opsonized tumor cells. Cancer Immunology/Immunotherapy, October, 55(10), 1238-46, 2006 |
| |
|
Dissanayake S, Rosenthal D, Hewitt K, Yang S, Wade M, Taub D, Nickoloff B, Trent J, Bittner M, Riker AI, Weeraratna A. Wnt5a regulates melanoma antigen recognized by T-cells-1 (MART-1), a predominant antigen in melanoma cells. Clinical Immunology, 119(1), S90, 2006
|
| |
| Riker AI, Sondak V, Daud A, Fishman M, Pilon-Thomas S: Current Immunotherapy of Melanoma. Clinical and Applied Immunology Reviews (CAIR), 5: 111-132, 2005 |
| |
|
Stennett LS, Riker AI, Kroll TM, Miki T, Schiffman D, Nickoloff BJ, LePoole IC: Expression of gp100 and CDK2 in melanoma cells is not co-regulated by a shared promoter region, Pigment Cell Research, 17: 525-532, 2004
|
| |
|
Riker AI. Isolation and culture of melanoma cell lines. Methods in Molecular Medicine, 88: 93-100, 2004
|
| |
| |
| |
| |
|
